肺肉类瘤癌患者的临床特征和生存结果:多中心回顾性研究
Zhijuan Du1,2, Yuhui Qin1,2, Yahui Lv1,2
1Medical School of Chinese PLA, Beijing, China.
概括
肺肉类瘤 (PSC) 显示了高的KRAS和EGFR突变率,状细胞癌表明预后较差. 免疫疗法可以改善晚期PSC患者的生存率.
科学领域:
- 在瘤学瘤学.
- 肺部医学 肺部医学
- 癌症遗传学 癌症遗传学
背景情况:
- 肺肉类瘤 (PSC) 是一种罕见且具有攻击性的非小细胞肺癌,临床病理特征和预后因素不明.
- 了解PSC的分子和临床特征对于开发向疗法和改善患者治疗结果至关重要.
研究的目的:
- 为了调查肺肉类瘤 (PSC) 的临床病理特征,突变状态和预后指标.
- 为了比较PSC与肺腺癌 (LUAD) 的结果,并评估PSC治疗中免疫治疗的疗效.
主要方法:
- 追溯分析了81例PSC病例和337例肺腺癌 (LUAD).
- 基于临床数据,瘤类型和TNM阶段的无进展生存 (PFS) 和总生存 (OS) 的检查.
- 分析KRAS和EGFR突变状态以及免疫治疗对生存的影响.
主要成果:
- 在PSC中,KRAS (46%) 和EGFR (23%) 突变的发病率很高.
- 在单变量和多变量分析中,瘤类型和cTNM阶段是PFS和OS的显著预测因素.
- 与LUAD相比,PSC显示PFS和OS明显更差. 用免疫疗法治疗的患者表现出改善的生存状况.
结论:
- 肺肉类瘤的特点是频繁的KRAS和EGFR突变,状细胞癌亚型与更糟糕的预后有关.
- 免疫疗法为晚期PSC提供了一个有前途的治疗选择,需要进一步研究.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:18Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
6.8K
相关概念视频
Cancer Survival Analysis
291
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
291
Kaplan-Meier Approach
52
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
52
Rous Sarcoma Virus (RSV) and Cancer
4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
4.9K
